For example, in the case of insufficient effects of ERBB2 inhibition due to the compensatory overexpression of the EGF receptor (EGFR) in cancer cells, administration of the ERBB2 inhibitor, Herceptin, is often combined with suppressing EGFR activity [7,8,9,10]. The gene discussed is ERBB2; the disease is cancer.